NCT06475625Active, not recruitingPhase 4
Clinical Impact of Orsiro™ Stent in Patient With Chronic Kidney Disease
Clinical Impact of Orsiro™ Stent in Patient With Chronic Kidney Disease Undergoing Percutaneous Coronay Intervention : A Multicenter, Prospective All-comers Registry
Source: ClinicalTrials.gov · Last updated 26 Jun 2024
Brief summary (registry, in English)
Orsiro™ or Orsiro\_Mission™ stents have the biodegradable polymer and the thinnest stent strut (60㎛) in commercially available stents, which could minimize chronic inflammation and incomplete endothelialization. In several prior studies, ultrathin strut sirolimus-eluting stent (Orsiro®) showed better outcomes in terms of target lesion failure or target lesion revascularization compared to other contemporary stents. Chronic kidney disease (CKD) is known to be associated with adverse cardiovascular outcome including restenosis or stent thrombosis following percutaneous coronary interventin (PCI), because the patients with CKD have more complex coronary lesion characteristics, severe calcification, and diffuse plaque of the coronary artery. However, there is a paucity of data regarding clinical efficacy of Orsiro® in CKD population. Therefore, this study aims to investigate the differences in clinical outcomes according to renal function in patients undergoing PCI with Orsiro™ or Orsiro\_Mission™ stents. After patients will be divided into three groups according to the renal function; normal or mild renal dysfunction (eGFR ≥ 60 ml·min - 1·1.73㎡), moderate renal dysfunction ( 30≤ eGFR\< 60 ml·min - 1·1.73㎡), and severe renal dysfunction (eGFR \< 30 ml·min -1·1.73㎡), the clinical outcome will be investigated among groups.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 3113 (actual)
- First submitted
- 18 Jun 2024
- Start date
- 22 Oct 2019
- Primary completion date
- 1 Jan 2025
- Lead sponsor
- The Catholic University of Korea
- NCT number
- NCT06475625
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 3113
- From 22 Oct 2019 to the primary completion date, 1 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient who used another drug-eluting stent for percutaneous coronary intervention at study registration time
Other
- Patient with a life expectancy of less than one year
- Cardiogenic shock
- Pregnancy
Who the study is looking for
- 19 years of age or older
- Patient undergoing percutaneous coronary intervention with Orsiro™ or Orsiro\_Mission™ stents
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Daejeon St. Mary's Hospital , The Catholic University of Korea Coordinator of this site? Confirm its status | Daejeon | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.